The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 21, 2012
Filed:
May. 14, 2009
Nicholas J Donato, Sugar Land, TX (US);
Doriano Fabbro, Arlesheim, CH;
Paul W Manley, Arlesheim, CH;
Jurgen Mestan, Denzlingen, DE;
Markus Warmuth, San Marcos, CA (US);
Michael Hallek, Cologne, DE;
Moshe Talpaz, Houston, TX (US);
Ji Wu, Houston, TX (US);
Nicholas J Donato, Sugar Land, TX (US);
Doriano Fabbro, Arlesheim, CH;
Paul W Manley, Arlesheim, CH;
Jurgen Mestan, Denzlingen, DE;
Markus Warmuth, San Marcos, CA (US);
Michael Hallek, Cologne, DE;
Moshe Talpaz, Houston, TX (US);
Ji Wu, Houston, TX (US);
Novartis AG, Basel, CH;
GSF-International Research Institute for Environment and Health, Oberschleissheim, DE;
Board of Regents, The University of Texas system, Austin, TX (US);
Abstract
The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.